1. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
- Author
-
Li, Zheqi, Filho, Otto Metzger, Viale, Giuseppe, dell'Orto, Patrizia, Russo, Leila, Goyette, Marie-Anne, Kamat, Avni, Yardley, Denise A., Abramson, Vandana Gupta, Arteaga, Carlos L., Spring, Laura M., Chiotti, Kami, Halsey, Carol, Waks, Adrienne G., King, Tari A., Lester, Susan C., Bellon, Jennifer R., Winer, Eric P., Spellman, Paul T., Krop, Ian E., and Polyak, Kornelia
- Subjects
Merck & Company Inc. -- Product development ,Genentech Inc. -- Product development ,Novartis AG -- Product development ,Agilent Technologies Inc. -- Product development ,AstraZeneca PLC -- Product development ,Eli Lilly and Co. -- Product development ,RNA sequencing ,Biotechnology industry -- Product development ,Pertuzumab ,B cells ,RNA ,Clinical trials ,Instrument industry -- Product development ,Breast cancer ,Pharmaceutical industry -- Product development ,Health care industry - Abstract
BACKGROUND. HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR). METHODS. To investigate cellular and molecular differences among tumors according to HER2 heterogeneity and pCR, we performed RNA sequencing and ERBB2 FISH of 285 pretreatment and posttreatment tumors from 129 patients in this T-DM1+P neoadjuvant trial. A subset of cases was also subject to NanoString spatial digital profiling. RESULTS. Pretreatment tumors from patients with pCR had the highest level of ERBB2 mRNA and ERBB signaling. HER2 heterogeneity was associated with no pCR, basal-like features, and low ERBB2 expression yet high ERBB signaling sustained by activation of downstream pathway components. Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K pathway enrichment and luminal features. HET tumors showed minimal treatment-induced transcriptomic changes compared with non-HET tumors. Immune infiltration correlated with pCR and HER2-HET status. CONCLUSION. Resistance mechanisms in HET and non-HET tumors are distinct. HER2-targeting antibodies have limited efficacy in HET tumors. Our results support the stratification of patients based on HET status and the use of agents that target downstream components of the ERBB signaling pathway in patients with HET tumors. TRIAL REGISTRATION. ClinicalTrials.gov NCT02326974. FUNDING. This study was funded by Roche and the National Cancer Institute., Introduction Breast cancer is one of the most prevalent and life-threatening malignancies in women worldwide (1). Breast cancer is a heterogeneous disease clinically classified on the basis of the expression [...]
- Published
- 2024
- Full Text
- View/download PDF